nuke
Credits:
2237
My Scrapbook
My Reading List
1 Books
|
Library: Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT)
|
07.23.05 (3 years ago)
#1
|
|
Two principal preliminary findings from ASCOT trial are:
1. Blood pressure treatment could cut risk of strokes and heart attacks A new treatment strategy for hypertension can cut the risk of strokes by around 25 percent and coronary events by around 15 percent, as well as significant reductions in cardiovascular mortality and all cause mortality.
2. The ‘first look’ at the data also found that those on the new treatment strategy had a one third less chance of developing diabetes compared with the older strategy.
Summary of trial:
The 19,000 patient Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT) had been comparing a new treatment strategy for hypertension, or high blood pressure, against an old one, in order to discover which is better at preventing various cardiovascular events such as heart attacks and strokes.
In November 2004, the trial was stopped after the Steering Committee of ASCOT accepted the recommendation of its Data Safety Monitoring Board that the blood pressure arm of the trial should be stopped, due to far better results for those patients on the new treatment.
The newer treatment strategy using the calcium channel blocker, amlodipine, and the angiotensin converting enzyme inhibitor, perindopril was compared with the older treatment strategy based on the beta-blocker, atenolol and the thiazide diuretic, bendroflumethiazide.
The complete results of the ASCOT trial will be made available when all data up to and including the last individual patient visit have been collected and analysed. Investigators and patients will be informed of the final results of ASCOT when these data become available. The results will be published in the scientific press.
Of over 19,000 patients randomised to the two different blood pressure strategies, approximately 10,000 patients were also randomised to treatment with either atorvastatin or placebo in the ASCOT Lipid Lowering Arm (ASCOT-LLA). The ASCOT-LLA was stopped prematurely in October 2002, as a result of substantial benefits associated with statin use in the prevention of heart attacks and strokes.
The principal sponsor of ASCOT is Pfizer Inc, New York. Support has also been provided by Servier Research Group, Paris and Leo Laboratories, Copenhagen.
|
|
|
Topic Tags: 
